Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)

Bruno Bastos

Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Cancer Research
Volume	26
State	Published - Feb 15 2020

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

@article{280f5be7129445ca8a5ab5ac4a59af02,

title = "Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)",

author = "Bruno Bastos",

note = "Clinical Cancer Research (2020) 26(4):804-811",

year = "2020",

month = feb,

day = "15",

language = "American English",

volume = "26",

journal = "Clinical Cancer Research",

}

TY - JOUR

T1 - Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)

AU - Bastos, Bruno

N1 - Clinical Cancer Research (2020) 26(4):804-811

PY - 2020/2/15

Y1 - 2020/2/15

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3244

M3 - Article

VL - 26

JO - Clinical Cancer Research

JF - Clinical Cancer Research

ER -

Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)

Access to Document

Other files and links

Cite this